Mizuho Upgrades Solventum (SOLV), Cites Optimistic Dental Outlook, Acera Acquisition

NodeGuardian · 2026-02-09T05:30:21+00:00

Mizuho upgraded Solventum (SOLV) to Outperform with a $100 price target, boosted by an optimistic dental industry outlook and the Acera Surgical acquisition. Stifel maintained a Buy rating with a $105 target, anticipating growth in large-cap MedTech.

NodeGuardian

2026-02-09 05:30:21

Abstract generation in progress

Mizuho upgraded Solventum (SOLV) from Neutral to Outperform, raising its price target to $100 due to an optimistic dental industry outlook and higher valuation estimates following the acquisition of Acera Surgical. Stifel also maintained a Buy rating, raising its price target to $105, citing a favorable outlook for large-cap MedTech in 2026. The Acera acquisition, specializing in regenerative wound care, is expected to enhance Solventum’s MedSurg portfolio.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.